Cargando…
Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
PURPOSE: Almost all cervical cancers are caused by human papillomavirus (HPV) and patients with advanced stage are at high risk for relapse. Circulating HPV DNA (HPV ctDNA) may serve as a residual tumor marker at the end of chemoradiation or to predict relapse during the follow-up period. EXPERIMENT...
Autores principales: | Jeannot, Emmanuelle, Latouche, Aurélien, Bonneau, Claire, Calméjane, Marie-Ange, Beaufort, Corine, Ruigrok-Ritstier, Kirsten, Bataillon, Guillaume, Larbi Chérif, Linda, Dupain, Célia, Lecerf, Charlotte, Popovic, Marina, de la Rochefordière, Anne, Lecuru, Fabrice, Fourchotte, Virginie, Jordanova, Ekaterina S., von der Leyen, Heiko, Tran-Perennou, Carine, Legrier, Marie-Emmanuelle, Dureau, Sylvain, Raizonville, Laurence, Bello Roufai, Diana, Le Tourneau, Christophe, Bièche, Ivan, Rouzier, Roman, Berns, Els M.J.J., Kamal, Maud, Scholl, Suzy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401545/ https://www.ncbi.nlm.nih.gov/pubmed/34210686 http://dx.doi.org/10.1158/1078-0432.CCR-21-0625 |
Ejemplares similares
-
HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports
por: Arfi, Alexandra, et al.
Publicado: (2019) -
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer
por: Scholl, Suzy M, et al.
Publicado: (2020) -
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
por: Kamal, Maud, et al.
Publicado: (2020) -
Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
por: Kamal, Maud, et al.
Publicado: (2023) -
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer
por: Cabel, L., et al.
Publicado: (2021)